Durham University

About: Durham University is a education organization based out in Durham, United Kingdom. It is known for research contribution in the topics: Population & Galaxy. The organization has 39385 authors who have published 82311 publications receiving 3110994 citations. The organization is also known as: University of Durham & Gallery of Durham University.

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.

Abstract: Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infection and disease were developed and most recently published in 2002. Since then, there have been major developments in its diagnosis and management. Therefore, the CMV Drug Development Forum consisting of scientists, clinicians, regulators, and industry representatives has produced an updated version incorporating recent knowledge with the aim to support clinical research and drug development. The main changes compared to previous definitions are the introduction of a "probable disease" category and to incorporate quantitative nucleic acid testing in some end-organ disease categories. As the field evolves, the need for updates of these definitions is clear, and collaborative efforts between scientists, regulators, and industry can provide a platform for this work.

Genomic instability in laminopathy-based premature aging

Abstract: Premature aging syndromes often result from mutations in nuclear proteins involved in the maintenance of genomic integrity. Lamin A is a major component of the nuclear lamina and nuclear skeleton. Truncation in lamin A causes Hutchinson-Gilford progerial syndrome (HGPS), a severe form of early-onset premature aging. Lack of functional Zmpste24, a metalloproteinase responsible for the maturation of prelamin A, also results in progeroid phenotypes in mice and humans. We found that Zmpste24-deficient mouse embryonic fibroblasts (MEFs) show increased DNA damage and chromosome aberrations and are more sensitive to DNA-damaging agents. Bone marrow cells isolated from Zmpste24−/− mice show increased aneuploidy and the mice are more sensitive to DNA-damaging agents. Recruitment of p53 binding protein 1 (53BP1) and Rad51 to sites of DNA lesion is impaired in Zmpste24−/− MEFs and in HGPS fibroblasts, resulting in delayed checkpoint response and defective DNA repair. Wild-type MEFs ectopically expressing unprocessible prelamin A show similar defects in checkpoint response and DNA repair. Our results indicate that unprocessed prelamin A and truncated lamin A act dominant negatively to perturb DNA damage response and repair, resulting in genomic instability which might contribute to laminopathy-based premature aging.

The All-Wavelength Extended Groth Strip International Survey(AEGIS) Data Sets

Abstract: In this the first of a series of Letters, we present a panchromatic data set in the Extended Groth Strip region of the sky. Our survey, the All-Wavelength Extended Groth Strip International Survey (AEGIS), aims to study the physical properties and evolutionary processes of galaxies at z ~ 1. It includes the following deep, wide-field imaging data sets: Chandra/ACIS X-ray, GALEX ultraviolet, CFHT/MegaCam Legacy Survey optical, CFHT/CFH12K optical, Hubble Space Telescope/ACS optical and NICMOS near-infrared, Palomar/WIRC near-infrared, Spitzer/IRAC mid-infrared, Spitzer/MIPS far-infrared, and VLA radio continuum. In addition, this region of the sky has been targeted for extensive spectroscopy using the Deep Imaging Multi-Object Spectrograph (DEIMOS) on the Keck II 10 m telescope. Our survey is compared to other large multiwavelength surveys in terms of depth and sky coverage.

Inserting device for a barbed tissue connector

Abstract: An inserting device is disclosed for positioning a barbed tissue connector in tissue to close a wound. The barbed tissue connector is of a type which includes a generally rigid elongated body having a pointed leading end and a plurality of axially spaced barbs on the elongated body. The inserting device comprises a tubular body which is adapted to receive the connector therein with the pointed leading end of the connector protruding from an open leading end of the tubular body. The inserting device and the connector contained therein are positioned in tissue such that at least one of the barbs on the connector is engaging tissue, and the device is then retracted from the tissue, leaving the connector in place.

erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

Abstract: Background We have previously reported that high expression of the erbB-2 gene (also known as HER-2/neu and ERBB2) in breast cancer is associated with patient response to dose-intensive treatment with cyclophosphamide, doxorubicin (Adriamycin), and 5-flurouracil (CAF) on the basis of short-term follow-up of 397 patients (set A) with axillary lymph node-positive tumors who were enrolled in Cancer and Leukemia Group B (CALGB) protocol 8541. Methods To validate those findings, we conducted immunohistochemical analyses of erbB-2 and p53 protein expression in an additional cohort of 595 patients (set B) from CALGB 8541, as well as a molecular analysis of erbB-2 gene amplification in tumors from all patients (sets A and B). Marker data were compared with clinical, histologic, treatment, and outcome data. Results Updated analyses of data from set A (median follow-up, 10.4 years) showed an even stronger interaction between erbB-2 expression and CAF dose, by use of either immunohistochemical or molecular data. A similar interaction between erbB-2 expression and CAF dose was observed in all 992 patients, analyzed as a single group. However, for set B alone (median follow-up, 8.2 years), results varied with the method of statistical analysis. By use of a proportional hazards model, the erbB-2 expression-CAF dose interaction was not significant for all patients. However, in the subgroups of patients randomly assigned to the high- or the moderate-dose arms, significance was achieved. When patient data were adjusted for differences by use of a prognostic index (to balance an apparent failure of randomization in the low-dose arm), the erbB-2 expression-CAF dose interaction was significant in all patients from the validation set B as well. An interaction was also observed between p53 immunopositivity and CAF dose. Conclusions The hypothesis that patients whose breast tumors exhibit high erbB-2 expression benefit from dose-intensive CAF should be further validated before clinical implementation. Interactions between erbB-2 expression, p53 expression, and CAF dose underscore the complexities of predictive markers where multiple interactions may confound the outcome.